ROLLOUT AS WELL. >>> DISTRIBUTION WILL HAPPEN IN FOUR PHASES BEGINNING WITH HEALTHCARE WORKERS AND RESPONDERS ON THE FRONT LINES. PHASE 1 IS THE ONLY FACE SPLIT INTO TWO DISTRIBUTION GROUPS. PHASE 1 A OUR HEALTHCARE WORKERS THAT HAVE DIRECT CONTACT WITH COVID PATIENTS IN LONG-TERM CARE STAFF. ADULTS WITH TWO OR MORE CHRONIC CONDITIONS. WE'VE ALREADY RECEIVED QUESTIONS ABOUT THIS NEXT GROUP, PHASE 2 INCLUDES EDUCATORS, ADULTS 18 TO 64 WITH ONE CHRONIC CONDITION AND ALL ADULTS OVER 65 INCLUDING THOSE WITH NO CHRONIC CONDITIONS. THERE IS A LOT TO UNPACK HERE AND WE WILL COME BACK TO THE DISTRIBUTION TOPIC IN JUST A MOMENT. >>> WE WANT TO START WITH TODAY'S HEARINGS AND DOCTOR SWAMI, YOU ARE A MEMBER OF THIS INDEPENDENT COMMITTEE REVIEWING PFIZER'S VACCINE. YOU ARE ALSO ON THE FRONT LINES OF THE PFIZER STUDY AT DUKE MEANING YOU WERE NOT ABLE TO EXPRESS YOUR THOUGHTS WITH THE FDA. SIMPLY PUT IT WOULD BE A CONFLICT OF INTEREST. THAT BEING SAID, WHAT'S THE BIGGEST TAKE AWAY FROM THE OPINIONS YOU HEARD TODAY? >> THANK YOU FOR HAVING ME THIS EVENING. IT WAS REALLY EXCITING TO HEAR THE INFORMATION AND THE DATA FROM THE TRIALS. I THINK THE CLEAR MESSAGE IS THAT THIS IS THE ONE OF THE MOST EFFECTIVE VACCINES THAT WE HAVE SEEN IN MODERN DAY. THE DATA SHOWING THE EFFICACY OR HOW WELL THE VACCINE WORKS WITH WAS RATHER IMPRESSIVE AND THE INFORMATION THEY'VE BEEN ABLE TO PROVIDE ABOUT SAFETY EVENTS IN THE IMMEDIATE TIMEFRAME AND THE FIRST FEW DAYS OR WEEK AFTER THE VACCINE, WAS ALSO VERY REASSURING BASED ON COMMON SYMPTOMS WE SEE AFTER VACCINE SUCH AS FEVER AND GENERAL ACHES AND PAINS. A LOT OF THOSE ARE FLULIKE SYMPTOMS THAT PEOPLE TALK ABOUT WITH VACCINES. GENERALLY SPEAKING THE MEETING WAS WELL RECEIVED, BUT IN THE END, I WAS VERY PLEASED TO SEE THE ADVISORY COMMITTEE APPROVED MOVING IT FORWARD. >> LET'S GO BACK TO THE DISTRIBUTION PROCESS AND LOGISTICS FOR A MOMENT. INDIVIDUAL STATES CARRY A GREAT WEIGHT OF RESPONSIBILITY OF GETTING THIS RIGHT. NORTH CAROLINA'S PLAY ON FOR EXAMPLE IS 150 PAGES. DOCTOR JULIE SWAN, AN OUTSIDER LOOKING AT THESE FINITE DETAILS MIGHT SAY SOMETHING IS BOUND TO GO WRONG, IN FACT DOCTOR COHEN SAID TODAY WITH ANYTHING THIS LARGE, MISTAKES ARE GOING TO HAPPEN. WITH THAT IN MIND, WHAT COULD GO WRONG IN A MASS DISTRIBUTION AND WHAT MEASURES ARE IN PLACE TO GET BACK ON TRACK? >> THE GOOD NEWS IS THAT THE STATE DEPARTMENT, THE STATE HEALTH DEPARTMENT IN NORTH CAROLINA HAS DONE AN EXCELLENT JOB. I'VE READ THAT 150 PAGE DOCUMENT THAT YOU ARE TALKING ABOUT. IT HAS A LOT MORE DETAIL THAN SOME OF THE STATE PLANS DO. YOU CAN REALLY SEE THAT NORTH CAROLINA HAS THOUGHT THROUGH SO MANY DIFFERENT ELEMENTS FROM SUB PRIORITY GROUPS, WITHIN GROUPS AND HOW MANY PEOPLE THERE ARE AND WHERE TO REACH THEM, SO WE WILL SEE SOME SNAGS ALONG THE WAY, THERE WILL BE QUESTIONS ABOUT THE VACCINE AND WHOSE TURN IS IT TO GET IT, BUT I THINK IN NORTH CAROLINA WE CAN BE VERY PROUD OF WHAT OUR STATE HEALTH DEPARTMENT AND OUR PARTNERS HAVE DONE. >> BOB INGRAM IS THE FORMER CEO OF GLAXO, WELCOME. CHILDREN AS WE KNOW ARE NOT INCLUDED AND THAT HAS SOME PEOPLE CONCERNED IN THIS PROCESS, HOW QUICKLY CAN WE EXPECT TO SEE THE TRIALS MOVE WITH CHILDREN? >> FIRST OF ALL, THANKS FOR HAVING ME. I THINK YOU WILL SEE CLINICAL TRIALS CONTINUE AND THEY WILL MOVE DOWN THE CHAIN TO YOUNGER POPULATIONS. THERE ARE CURRENTLY TRIALS IN CHINA THAT GO DOWN TO THE AGE OF THREE BUT I WOULD REFER TO DOCTOR SWAMI PARTICULARLY BUT BETWEEN A 16-YEAR-OLD IN LET'S SAY AN 18 TO 19-YEAR-OLD, THERE'S NOT A LOT OF DIFFERENCE IN TERMS HOW OF HOW PEOPLE WILL REACT TO THIS TO VACCINE SO I'M REALLY ENCOURAGED AND I COMMEND THE ADVISORY COMMITTEE ON THE THOROUGHNESS OF THE REVIEW, I THINK IT'S HIGHLY LIKELY THE FDA WILL MOVE FAST AND APPROVE THE EMERGENCY USE OF THIS VACCINE AND THE REAL GOOD NEWS HERE IS THAT THIS IS THE FIRST OF WHAT I THINK WILL BE SEVERAL VACCINES. THERE WILL BE THE MODERNA ONE CLOSE BEHIND, ANOTHER COMING AFTER THAT. THERE ARE ABOUT NINE AND PHASE 3 TRIALS SO IT COULD BE LIKE ROLLING THUNDER OVER THE NEXT SEVERAL MONTHS WHERE WE SEE SEVERAL VACCINES THAT ARE APPROVED AND AVAILABLE AND I WOULD URGE ALL OF AMERICANS WHO ARE ELIGIBLE TO TAKE THESE VACCINES, TO TAKE THEM AS SOON AS POSSIBLE. >> WE WILL TALK MORE ABOUT SOME OF THAT RELUCTANCE IN A MINUTE. DOCTOR SWAMI, WE WANT TO GO BACK TO YOU AND TALK ABOUT THE CHILDREN. USUALLY WE SEE CHILDREN GETTING THE MEASLES VACCINES, YOU THINK OF CHILDREN BEING THE FIRST TO GET THE VACCINE SO IS THERE A CONCERN IN YOUR EYES THAT CHILDREN ARE NOT AMONG THIS FIRST WAVE? >> IT'S CERTAINLY WHAT WE WOULD REALLY LOVE TO SEE IS THAT EVERYONE WHO WE WOULD WANT TO BE ABLE TO GIVE A VACCINE TO HAS BEEN STUDIED. IF YOU KEEP IN MIND THAT THIS HAS REALLY BEEN AN INCREDIBLE PACE OF RESEARCH, THIS IS TRULY UNPRECEDENTED. I KNOW THAT WORD IS USED A LOT, BUT HONESTLY THE FACT THAT WE HAVE DATA ON SOME 40,000 PARTICIPANTS IN THIS STUDY AND ANOTHER 30,000 COMING NEXT WEEK IS A TESTAMENT TO WHAT WE CAN DO. I WOULD LIKE TO SEE DATA AND CHILDREN ABSOLUTELY. THE DATA THAT PFIZER PRESENTED TODAY HAS INFORMATION SHOWN FOR INDIVIDUALS OF 16 OR 17 YEARS OF AGE SO THAT IS A SMALL POPULATION IN THE PEDIATRIC REALM BUT THEY ARE CONSISTENT WITH WHAT WE'VE BEEN EXPECTING AND YOUNG ADULTS AS WELL. THERE ARE PLANS TO DO STUDIES IN THE U.S. IN CHILDREN AS WELL. I THINK ONE OF THE THINGS THAT HOLD SOME OF THAT BACK THAT WE DON'T EXACTLY KNOW THE RIGHT DOSE. WE CAN'T THINK OF CHILDREN AS JUST SMALL ADULTS. WE NEED TO THINK ABOUT THEM ACROSS THE AGE SPECTRUM SO THE PLAN RIGHT NOW IS JUST TO CONTINUE DOWN THAT AGE RANGE AND THE OTHER FACTOR IN ALL THAT IS WHILE IT IS REALLY IMPORTANT TO KNOW THAT CHILDREN OFTEN SERVE AS THE VECTOR IF WE OPEN UP OUR SCHOOLS THEY WILL BE IN CLOSE CONTACT, WE WANT OUR CHILDREN TO BE OUT THERE SOCIALIZING AND HAVING FUN BUT WE ALSO KNOW IT'S PROBABLY HARD TO THINK ABOUT THEM BEING ABLE TO DISTANCE AND MASK AS MUCH AS ADULTS CAN SO WE HAVE TO BALANCE THAT WITH THE RISK OF THEM GETTING INFECTED VERSUS TRANSMITTING TO OTHERS AND THE LAST THING IS TO NOTE THAT WHILE CHILDREN HAVE GOTTEN SICK, THANKFULLY THEY HAVE NOT BEEN IN THOSE CATEGORIES OF HAVING SEVERE DISEASE SO WELL WE WOULD REALLY LIKE TO SEE THE VACCINATIONS FOR KIDS WHICH ABSOLUTELY WE SHOULD CONTINUE TO PURSUE AND IT SHOULD BE FORTHCOMING, I THINK IT'S OKAY RIGHT NOW THAT WE GO WITH WHAT WE HAVE THE DATA ON. >> THIS IS ALL MOVING VERY QUICKLY. THIS CONVERSATION IS JUST GETTING STARTED. WE TAKE YOUR QUESTIONS TO OUR PANEL COMING UP HERE >>> EVEN IF IT'S APPROVED, PEOPLE STILL HAVE TO TAKE THE VACCINE FOR IT TO BE EFFECTIVE IN ACHIEVING HERD IMMUNITY. CONVINCING ENOUGH OF THE PUBLIC